GlassScriptPhysician profile
Jose C Rafecas
NPI 1598728149
$3,265.91
in general payments reported to CMS, 2019-2025
40 companies · none reported in 2025
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $3,118 · 2020: $129 · 2021: $5.79 · 2022: $12.57.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $428.02 | 2019 | |
| Alexion Pharmaceuticals, INC. | $350.72 | 2019-2020 | |
| Emd Serono, INC. | $301.19 | 2019 | |
| Eisai INC. | $221.86 | 2019-2020 | |
| Novartis Pharmaceuticals Corporation | $209.58 | 2019-2020 | |
| Genentech, INC. | $207.42 | 2019 | |
| Biogen, INC. | $184.06 | 2019 | |
| Ucb, INC. | $152.47 | 2019 | |
| Jazz Pharmaceuticals INC. | $133.34 | 2019 | |
| Amgen INC. | $125.81 | 2019 | |
| Grifols USA, LLC | $97.18 | 2019 | |
| Lundbeck LLC | $88.47 | 2019 | |
| Neurocrine Biosciences, INC. | $84.78 | 2019-2020 | |
| Sunovion Pharmaceuticals INC. | $70.84 | 2019 | |
| Genentech USA, INC. | $66.44 | 2019 |
Show all 39 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $54.69 | 2019 | |
| Kyowa Kirin, INC. | $38.91 | 2019-2020 | |
| Supernus Pharmaceuticals, INC. | $35.78 | 2019-2020 | |
| Acorda Therapeutics, INC | $32.14 | 2019 | |
| Merz North America, INC. | $31.67 | 2019 | |
| Tanabe Pharma America, INC. | $30.52 | 2019 | |
| Ge Healthcare | $29.17 | 2020-2022 | |
| Avanir Pharmaceuticals, INC. | $27.53 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $25.12 | 2019 | |
| Ironshore Pharmaceuticals INC. | $22.27 | 2019 | |
| Adamas Pharmaceuticals, INC. | $21.61 | 2019 | |
| Csl Behring | $19.73 | 2019 | |
| Saol Therapeutics INC. | $19.63 | 2019 | |
| Aquestive Therapeutics, INC. | $18.66 | 2019 | |
| Mdd US Operations, LLC | $15.07 | 2019 | |
| Zyla Life Sciences, INC. | $14.50 | 2019 | |
| Horizon Therapeutics Plc | $12.56 | 2020 | |
| Mallinckrodt Enterprises LLC | $12.35 | 2019 | |
| Medtronic Vascular, INC. | $12.18 | 2019 | |
| Abbott Laboratories | $12.01 | 2019 | |
| Vertical Pharmaceuticals, LLC | $11.88 | 2019 | |
| Strongbridge US INC. | $11.80 | 2019 | |
| Pfizer INC. | $11.59 | 2019 | |
| Lilly USA, LLC | $10.87 | 2019 |
1 company reported research payments only; those appear in the research section below.
Research and ownership
$996.80 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jose Rafecas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.